SARS News and Research

RSS

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Researchers compare the obtained binding affinities to wild-type and Delta spike proteins to determine the impact of Omicron mutations.

23 Dec 2021

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Researchers develop a new allele-specific RT-qPCR to detect the SARS-CoV-2 Omicron variant in wastewater.

23 Dec 2021

Children produce a much more robust antibody response to a SARS-CoV-2 infection than 18+

Scientists compared receptor binding domain antibodies and SARS-CoV-2 neutralizing antibodies in children and adults.

23 Dec 2021

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Scientists used virus-like particles and found that Omicron showed increased infectivity, relative to the B.1 and B.1.1 strains, which was similar to the Delta variant.

23 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

Coinfection of SARS-CoV-2 and human rhinovirus associated with more severe health outcomes

Researchers discuss the incidence and effect of coinfections with SARS-CoV-2 and human rhinovirus.

23 Dec 2021

Spatiotemporal patterns of Delta variant progression and its associated health interventions

In a new study, researchers adopted a prospective space-time scan method to conduct spatiotemporal analysis at the district level in the seven selected countries in SEA from June 2021 to October 2021.

23 Dec 2021

Impact of the rapid spread of the SARS-CoV-2 Omicron variant in Southern Africa

A new study has focused on the genomic profile and early transmission dynamics of Omicron. This study revealed the dominance of the Omicron variant in regions with high levels of population immunity.

23 Dec 2021

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

A new study describes the findings of a seroprevalence survey intended to establish the infection rates and the incidence of severe COVID-19 through December 15, 2021, in Gauteng, a crowded province that compresses a quarter of the country’s people into less than 2% of its area.

23 Dec 2021

Assessing the clinical severity of the SARS-CoV-2 Omicron variant

A recent preprint examines the proportion of Omicron infection and the risk of severe disease with this variant of SARS-CoV-2.

23 Dec 2021

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

A new study examines the impact of the Omicron variant on hospitalizations among children in South Africa.

23 Dec 2021

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

A new study shows that both antibody and cellular arms of the adaptive immune response against SARS-CoV-2 are displayed strong, sustained, and cross-reactive against other coronaviruses, in young children than the immune responses in adults.

23 Dec 2021

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

In a study posted to the bioRxiv* pre-print server, a team of researchers conducted a structure-activity relationship study of boceprevir-based molecules to find antiviral drug candidates targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease MPro.

22 Dec 2021

Survey finds acceptable levels of COVID-19 awareness and preparedness among healthcare workers

A survey of healthcare workers in 57 countries found that while overall preparedness for and awareness of the COVID-19 pandemic were at levels deemed acceptable during the first wave, significant differences in these levels were seen across worker groups and countries.

22 Dec 2021

The transmission dynamics of SARS-CoV2 Omicron variant

In a recent study posted to the medRxiv* preprint server, researchers developed a coronavirus disease (COVID-19) model-inference system in South Africa to determine transmission dynamics and immune evasion associated with severe acute respiratory syndrome-associated coronavirus disease (SARS-CoV-2) Omicron variant.

22 Dec 2021

How the SARS-CoV-2 Delta variant grew to dominate the UK epidemic

Researchers examine SARS-CoV-2 genomes in England to evaluate the effectiveness of COVID-19 policies.

22 Dec 2021

Decline in protection against SARS-CoV-2 Omicron in prior infected and fully vaccinated

In a recent study posted to the medRxiv* preprint server, researchers investigated the distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants among coronavirus disease 2019 (COVID-19) positive individuals who were either naive, fully vaccinated, or had a previous infection to further investigate possible escape from vaccine- or infection-induced immunity by Omicron compared to Delta.

22 Dec 2021

Scientists develop methods to quantify the transmissibility of new COVID-19 variants

As the discovery of the new omicron variant illustrates, new COVID-19 variants will continue to regularly emerge.

22 Dec 2021

SARS News and Research

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Children produce a much more robust antibody response to a SARS-CoV-2 infection than 18+

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Coinfection of SARS-CoV-2 and human rhinovirus associated with more severe health outcomes

Spatiotemporal patterns of Delta variant progression and its associated health interventions

Impact of the rapid spread of the SARS-CoV-2 Omicron variant in Southern Africa

Exploring why children have milder COVID-19 infections compared to adults

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

Assessing the clinical severity of the SARS-CoV-2 Omicron variant

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

Survey finds acceptable levels of COVID-19 awareness and preparedness among healthcare workers

The transmission dynamics of SARS-CoV2 Omicron variant

How the SARS-CoV-2 Delta variant grew to dominate the UK epidemic

Decline in protection against SARS-CoV-2 Omicron in prior infected and fully vaccinated

Scientists develop methods to quantify the transmissibility of new COVID-19 variants

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News